|
""Born to be Bad"": Is Abnormal Cell Mobility Already Present At Initiation?
|
1R21CA185016-01
|
$214,618
|
SHIBATA, DARRYL
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
""Comparative gene resequencing in mouse cancer models""
|
5K08CA160658-04
|
$180,360
|
MCFADDEN, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies
|
1P20CA192990-01
|
$177,045
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
(PQA-2) Reprogramming of circulating adipose stromal cells by mechanical stress
|
1R21CA184084-01
|
$193,160
|
LI, RONG
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
1R01CA190092-01
|
$555,711
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQA1) Novel epigenetic mechanism mediate metformin inhibition of prostate cancer
|
5R01CA180277-02
|
$267,356
|
LI, XIN
|
NEW YORK UNIVERSITY
|
|
(PQA1) The antipsychotic thioridazine protects against medulloblastoma (MB): volu
|
1R01CA185039-01
|
$386,223
|
JAN, LILY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
|
1R01CA184820-01
|
$399,474
|
DUBOIS, RAYMOND
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
(PQA1)Toward understanding mechanisms of COX-2 driven metastasis of breast cancer
|
1R21CA185226-01
|
$202,221
|
LYONS, TRACI
|
UNIVERSITY OF COLORADO DENVER
|
|
(PQA2) MAMMALIAN REGENERATION, HIGH FAT DIETS, AND BREAST CANCER: A COMMON LINK?
|
5R01CA180070-02
|
$345,551
|
HEBER-KATZ, ELLEN
|
WISTAR INSTITUTE
|
|
(PQB-4) Single cell analysis strategy for monitoring drug responses of tumors
|
1R01CA190122-01
|
$591,830
|
TIAN, QIANG
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
|
(PQB6) Accurate Comparative Genome-wide Analysis of Primary Tumors and Metastases
|
5R21CA180016-02
|
$166,671
|
WOTTON, DAVID
|
UNIVERSITY OF VIRGINIA
|
|
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer
|
7R01CA179991-02
|
$354,825
|
IACOBUZIO-DONAHUE, CHRISTINE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
|
5R01CA180149-02
|
$557,736
|
AGUS, DAVID
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQB6)Elucidating metastasis by real-time monitoring and tagging of CTCs in GEMMs
|
1R01CA184956-01
|
$616,479
|
MANALIS, SCOTT
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
|
1R01CA185457-01
|
$1,044,796
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
|
1R01CA190027-01
|
$383,875
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS
|
1R01CA185138-01
|
$486,312
|
HWANG, EUN-SIL
|
DUKE UNIVERSITY
|
|
(PQC3) Using an Immunoscore to Assess Tumor-medicated Immune Variations in Africa
|
1R21CA190076-01
|
$127,238
|
WALLACE, TIMOTHY
|
BON SECOURS RICHMOND COMMUNITY HOSPITAL
|
|
(PQC4) Fate of cells disseminating from human breast cancer xenografts
|
5R01CA180039-02
|
$318,015
|
WERB, ZENA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQC5 in RFA-CA-12-020) Using MR phase to detect ferritin tagged breast cancer ce
|
1R21CA184682-01
|
$198,360
|
HU, JIANI
|
WAYNE STATE UNIVERSITY
|
|
(PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resist
|
5R21CA179970-02
|
$162,451
|
GAO, ALLEN
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
1R01CA185151-01
|
$603,086
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD3) The role and therapeutic potential of ZNF304 in Ovarian Cancer
|
5R21CA180145-02
|
$168,781
|
OZPOLAT, BULENT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQD4) SIGNS OF INFLAMMATORY BREAST CANCER ARE CAUSED BY STROMAL FIELD EFFECTS
|
3R01CA180061-02S1
|
$111,758
|
WOODWARD, WENDY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQD4) SIGNS OF INFLAMMATORY BREAST CANCER ARE CAUSED BY STROMAL FIELD EFFECTS
|
5R01CA180061-02
|
$393,713
|
WOODWARD, WENDY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
1P20CA192973-01
|
$191,836
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
18F-Fluorocholine to distinguish necrosis from recurrence in brain metastases
|
5R21CA170289-02
|
$355,854
|
BEAL, KATHRYN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
2/2 Florida Minority Cancer Research & Training Center: Feasibility Studies
|
1P20CA192992-01
|
$171,144
|
ODEDINA, FOLAKEMI
|
UNIVERSITY OF FLORIDA
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
1P20CA192976-01
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
27-hydroxycholesterol as a link between obesity and breast cancer pathogenesis
|
5K99CA172357-02
|
$94,829
|
NELSON, ERIK
|
DUKE UNIVERSITY
|
|
27-hydroxycholesterol as a link between obesity and breast cancer pathogenesis
|
4R00CA172357-03
|
$241,148
|
NELSON, ERIK
|
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
|
|
3D-Adhesion Stromagenesis in Cancer Permissiveness
|
5R01CA113451-08
|
$327,986
|
CUKIERMAN, EDNA
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
|
5R44CA132257-04
|
$522,886
|
MORGAN, LEE
|
DEKK-TEC, INC.
|
|
4D Microfluidic Platforms for Targeting Breast Cancer:Lymphatic Interactions
|
5R21CA175931-02
|
$160,342
|
SLOANE, BONNIE
|
WAYNE STATE UNIVERSITY
|
|
99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries
|
1R44CA180390-01A1
|
$165,917
|
COPE, FREDERICK
|
NAVIDEA BIOPHARMACEUTICALS, INC.
|
|
A 3-D In Vitro Platform of Tumor Metastasis (PQ24)
|
7R01CA170879-03
|
$332,671
|
GEORGE, STEVEN
|
WASHINGTON UNIVERSITY
|
|
A Droplet-Based System for Capture, Manipulation, and Biochemical Profiling of R
|
5R21CA177447-02
|
$258,437
|
JEFFREY, STEFANIE
|
STANFORD UNIVERSITY
|
|
A Genetic Screen for HCC Genes
|
5R01CA132962-05
|
$293,831
|
LARGAESPADA, DAVID
|
UNIVERSITY OF MINNESOTA
|
|
A Genetically Defined System to Identify Factors Essential for KRas Oncogenesis
|
1R21CA176561-01A1
|
$159,818
|
COLLISSON, ERIC
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A High-Throughput Model for Human Melanoma
|
2R01CA121118-06A1
|
$250,535
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A micro Hall chip for circulating microvesicle based cancer monitoring
|
1R21CA182336-01A1
|
$230,692
|
ISSADORE, DAVID
|
UNIVERSITY OF PENNSYLVANIA
|
|
A microRNA based prognostic service that predicts melanoma metastasis likelihood
|
1R43CA183092-01
|
$199,654
|
KURTH, ISABEL
|
RGENIX, INC.
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$101,762
|
Kelly Siebenlist, Kathleen
|
CCR (NCI)
|
|
A molecular mechanism whereby metformin protects against liver cancer
|
1R21CA185021-01
|
$189,664
|
XIAO, HUA
|
MICHIGAN STATE UNIVERSITY
|
|
A nanosystem for tumor treatment and imaging
|
1R01CA188883-01A1
|
$404,625
|
RUOSLAHTI, ERKKI
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5U01CA166894-02
|
$358,782
|
SUN, ZIJIE
|
STANFORD UNIVERSITY
|
|
A new radiopharmaceutical for the treatment of metastatic bone cancer
|
5R44CA150601-03
|
$701,849
|
SIMON, JAIME
|
ISOTHERAPEUTICS GROUP, LLC
|
|
A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment
|
1R43CA183223-01
|
$224,734
|
PRUDENT, JAMES
|
CENTROSE, LLC
|
|
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER
|
1F30CA189435-01
|
$29,179
|
SOM, AVIK
|
WASHINGTON UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|